Objective. To evaluate the effectiveness of the application of levocarnitine solutions for injections and intramuscular administration under the conditions of a daytime outpatient facility for the treatment of the patients presenting with trophic ulcers of venous etiology. Material and methods. The present prospective observational study included 60 patients suffering from varicose vein disease and open trophic ulcers (C6S, Ep, As,p, Pr). They were divided into two groups. The first (main) group consisted of 30 patients given levocarnitine. The second (control) group included 30 patients treated without this preparation. The fractions of the patients with trophic ulcers healed and the time needed for the appearance of positive changes in ulcerative defects were compared after the completion of the course of the treatment. The quality of life of the patients was estimated with the use of the CIVIQ20 questionnaire. Results. The patients of both groups were matched for sex, age, duration and severity of the disease. The main group comprised 21 (70%) women and 9 (30%) men while the control group included 19 (63.3%) women and 11 (36.7%) men. The mean age of the patients in the main and control groups was 63±20 years and 64±20 years respectively. The duration of ulcers was 5.62±2.35 and 6.16±2.84 months respectively, their area 3.89±5.13 and 4.18±6.52 sq. cm. In 27 (90%) of the patients of the main group and in 18 (60%) ones in the control group, the treatment resulted in the reduction of discharge from the ulcers and the cleansing of their surfaces from fibrin (p=0.02). On day 75 after the onset of the treatment, complete healing of the ulcers was documented in 5 (17%) and 3 (11%) patients of the main and control groups respectively (p<0.05). The quality of life of the patients in both group was improved appreciably by day 30. Conclusion. The cleansing of the ulcer surfaces from fibrin deposition and the reduction of discharge from the ulcers occurs more rapidly in the patients treated with levocarnitine in addition to conventional therapy compared with those receiving no levocarnitine.